Erratum: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 (Clin Cancer Res (2021) 27 (5236-5247)DOI: 10.1158/1078-0432.CCR-21-0715)
- Mansoor N. Saleh
- , Manish R. Patel
- , Todd M. Bauer
- , Sanjay Goel
- , Gerald S. Falchook
- , Geoffrey I. Shapiro
- , Ki Y. Chung
- , Jeffrey R. Infante
- , Robert M. Conry
- , Guilherme Rabinowits
- , David S. Hong
- , Judy S. Wang
- , Ulrich Steidl
- , Loren D. Walensky
- , Gurudatta Naik
- , Vincent Guerlavais
- , Vojislav Vukovic
- , D. Allen Annis
- , Manuel Aivado
- , Funda Meric-Bernstam
Research output: Contribution to journal › Comment/debate
4
Citations
(Scopus)